Comparison of Human Papilloma Virus Results in Women with and without Atopic Disease

Gülsüm Uysal; Güzin Özden; Şevki Göksun  Gökulu

doi:10.58600/eurjther-28-4-0032

Authors

Gülsüm Uysal Adana City Training and Research Hospital, Department of Obstetrics and Gynecology, Adana, Turkey https://orcid.org/0000-0002-9381-4892
Güzin Özden Adana City Training and Research Hospital, Division of Allergy and Immunology, Adana,Turkey https://orcid.org/0000-0003-4856-2267
Şevki Göksun Gökulu Mersin University, Division of Gynecologic Oncology, Mersin, Turkey https://orcid.org/0000-0002-6581-5716

DOI:

https://doi.org/10.58600/eurjther-28-4-0032

Keywords:

Human papilloma virus, screening test, atopic diseases, asthma, rhinitis, urticaria

Abstract

Objective: Virus infected cells are destroyed by the natural immune system. However, HPV genotype and concomitant diseases are effective in HPV persistence. The aim of the study is to compare HPV screening results between patients with and without atopic disease.

Methods: This cross-sectional controlled study was conducted between August 2019 February 2020 in a tertiary research hospital. Patients between the ages of 30-65 with allergic complaints were diagnosed “atopic disease” by same clinician. HPV test results were compared to healthy controls. Subgroup atopic disease diagnoses, duration of illness, treatments regimes and treatment time of the patients in the study group were also questioned and recorded.

Results: A total of 239 women were recruited (121 study and 118 controls). Of recruited 121 atopia diagnosed women, 65 had rhinitis,9 had urticaria, 20 had asthma and remaning 27 had both rhinitis and asthma. 9 patients in control group and 7 patients in study group were HPV positive. No cervical carcinoma was reported. The mean duration of atopia was 50 months (12-360). 78 patients were treated medicaly while 43 were vaccinated during medical therapy

Conclusion: HPV test results of groups were similar. No extra screening schedules are needed for patients with atopic diseases such as asthma, rhinitis or urticaria.

Metrics

Metrics Loading ...

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7-34.

Schiffman M, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human Papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85:958-64.

Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020; 471:88-102.

Yıldırım D. Gökaslan H. Serviks kanseri taramasında HPV DNA testinin yeri. Türk Jinekolojik Onkoloji Dergisi 2015;1:1-6.

Ozgul N, Tuncer M, Abacioglu M, Gultekin M. Estimating Prevalence of Genital Warts in Turkey: Survey among KETEM-affiliated Gynecologists across Turkey. Asian Pacific J Cancer Prev, 2011;12:2397-440.

Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J. Obstet. Gynaecol, 2007; 33:103- 13.

Raposo A, Tani C, Costa J, Mosca M. Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review. Acta Reumatol Port 2016; 41: 184-90.

Shi LH, Huang JY, Liu YZ, Chiou JY, Wu R, Wei JCC. Risk of systemic lupus erythematosus in patients with human papillomavirus infection: a population-based retrospective cohort study. Lupus 2018; 27: 2279-83.

Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013; 68:974-82.

Garritsen F.M., Verheijen R.H.M., Gerestein C.G., Van Zuilen A.D., Oosterhaven J.A.F., Van Dijk M. et al. Is there an in-creased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs? JEADV 2018; 32:271-75.

Morgan TK, Hanifin J, Mahmood M, Larson B, Baig-Lewis S, Long T,et al. Atopic Dermatitis Is Associated With Cervical High Risk Human Papillomavirus Infection? J Lower Gen Tract Dis 2015;19: 345-59.

Montgomery S, Ehlin A, Sparen P, Bjorksten B, Ekborn A. Childhood indicators of susceptibility to subsequent cervical cancer. Br J Cancer 2002; 87:989-93.

Morrison EA, Dole P, Sun XW, Stern L, Wright TC Jr. Low prevalence of human papillomavirus infection of the cervix in renal transplant recipients. Nephrol Dial Transplant. 1996;11:1603-06.

Pietrzak B, Mazanowska N, Ekiel AM, Durlik M, Martirosian G, Wielgos M, et al. Prevalence of high-risk human papillomavirus cervical infection in female kidney graft recipients: an observational study. Virol J. 2012; 9:117.

Origoni M, Stefani C, Dell’Antonio G, Carminati G, Parma M, Candiani M. Cervical Human Papillomavirus in transplanted Italian women: a long-term prospective follow-up study. J Clin Virol. 2011; 51:250-54.

Meeuwis KA, Melchers WJ, Bouten H, van de Kerkhof PC, Hinten F, Quint WG, et al. Anogenital Malignancies in Women After Renal Transplantation Over 40 Years in a Single Center. Transplantation. 2012; 93:914-22.

Kim SC, Glynn RJ, Giovannucci E, Hernández-Díaz S, Liu J, Feldman S, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015; 74:1360-67.

Sugita K, Kabashima K. Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases. J Leukoc Biol. 2020 Feb 28.

Brusselle GG, Maes T, Bracke KR. Bedside to bench: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013;19:977-79.

Deligeoroglou E, Giannouli A, Athanasopoulos N, Karountzos V ,Vatopoulou A, Dimopoulos K, et al. HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol 2013; 2013: 540850.

Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002; 347:1151-60.

McFarlane M, MacDonald AI, Stevenson A, Graham SV2. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).J Virol. 2015; 89:5276-87.

Klymenko T, Hernandez-Lopez H, MacDonald AI, Bodily JM, Graham SV. Human Papillomavirus E2 Regulates SRSF3 (SRp20) To Promote Capsid Protein Expression in Infected Differentiated Keratinocytes. J Virol. 2016; 90:5047-58.

Issouf M, Vargas A, Boivin R, Lavoie JP. SRSF6 is upregulated in asthmatic horses and involved in the MYH11 SMB expression. Physiol Rep. 2018; 20:13896.

Feist H, Hussein K, Stucki-Koch A, Wohlschlaeger J, Hager T, Blöcker T, et al. Villitis of unknown etiology and chronic deciduitis are not associated with human papilloma virus and enterovirus infection. Virchows Arch. 2020; 1:73-81.

Kim CJ, Romero R, Chaemsaithong P, Kim JS. Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance. Am J Obstet Gynecol. 2015;4:53-69.